Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The LINFU® U.S. Registry for the Detection of Dysplasia and Pancreatic Ductal Adenocarcinoma (PDAC) in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas)

NCT06276764 is registered in ClinicalTrials.gov with Adenocyte, LLC as lead sponsor.

NCT NCT06276764
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06276764 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The LINFU® U.S. Registry for the Detection of Dysplasia and Pancreatic Ductal Adenocarcinoma (PDAC) in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas)
Lead sponsor
Adenocyte, LLC
Phase
Observational
Overall status
Enrolling by invitation
Start date
October 15, 2024
Completion date
December 1, 2034
Enrollment
500 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ipmn, pancreatic, pancreas cancer, pancreatic cyst